Christopher Kiper
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Christopher Kiper
Christopher Kiper was last confirmed as Board Member at Lifecore Biomedical, Inc. \De\ (LFCR) in a filing dated September 23, 2024. Lifecore Biomedical, Inc. \De\ reported in an 8-K filed January 10, 2023 that Christopher Kiper was appointed Class 1 director (Series A Preferred Director). Lifecore Biomedical, Inc. \De\ reported in an 8-K filed January 10, 2023 that Christopher Kiper was appointed Class 1 Director, effective January 9, 2023.
“The initial Series A Preferred Directors shall be Nathaniel Calloway and Christopher Kiper, who shall be appointed to the Board immediately following the Closing. Christopher Kiper shall be appointed to serve as a Class 1 director with a term expiring at the 2024 annual meeting of the Company's stockholders or such individual's earlier resignation, death or removal.”
“Pursuant to the Series A Director Right and effective as of the Closing Date, the Board appointed Nat Calloway, 40, to the Board as a new Class 2 director, and Christopher Kiper, 52, as a Class 1 Director.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2023-01-01–2024-09-23
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.